RT Journal Article SR Electronic T1 Hypermethylation of Corticotropin Releasing Hormone Receptor-2 Gene in Ulcerative Colitis Associated Colorectal Cancer JF In Vivo JO In Vivo FD International Institute of Anticancer Research SP 57 OP 63 DO 10.21873/invivo.11745 VO 34 IS 1 A1 MASAYOSHI KOBAYASHI A1 NAGAHIDE MATSUBARA A1 YUTAKA NAKACHI A1 YASUSHI OKAZAKI A1 MOTOI UCHINO A1 HIROKI IKEUCHI A1 JIHYNG SONG A1 KEI KIMURA A1 MICHIKO YASUHARA A1 AKIHITO BABAYA A1 TOMOKI YAMANO A1 MASATAKA IKEDA A1 HIROKI NISHIKAWA A1 IKUO MATSUDA A1 SEIICHI HIROTA A1 NAOHIRO TOMITA YR 2020 UL http://iv.iiarjournals.org/content/34/1/57.abstract AB Background/Aim: The difficulty of early diagnosis of colitis associated colorectal cancer (CACRC) due to colonic mucosal changes in long-standing ulcerative colitis (UC) patients is often experienced in daily clinical practice. Noninvasive objective monitoring for cancer development is advantageous for optimizing treatment strategies in UC patients. We aimed to examine the epigenetic alterations occurring in CACRC, focusing on DNA hypermethylation of CpG islands. Materials and Methods: The level of DNA methylation in CpG cites was compared between CACRC and the counterpart non-tumorous mucosa using Infinium HumanMethylation 450K BeadChip. Results: Our subjects included 3 males and 3 females (median age, 49.5 years). The 450K CpG site DNA methylation microarray revealed that the difference in β value (level of hypermethylation) was the highest for corcicotropin releasing hormone receptor 2 (CRHR2) between CACRC and counterpart non-tumorous mucosa. Conclusion: Detection of hypermethylation of CRHR2 may be promising for cancer screening in UC patients.